Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
JALYN vs ACETAMINOPHEN AND CODEINE PHOSPHATE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Jalyn is a combination of dutasteride, a 5α-reductase inhibitor that inhibits the conversion of testosterone to dihydrotestosterone (DHT), and tamsulosin, an α1-adrenoceptor antagonist that relaxes smooth muscle in the prostate and bladder neck.
Acetaminophen: centrally acting analgesic and antipyretic, possibly via inhibition of cyclooxygenase (COX) and modulation of cannabinoid receptors. Codeine: prodrug converted to morphine; mu-opioid receptor agonist.
Treatment of symptomatic benign prostatic hyperplasia (BPH),Reduction in risk of acute urinary retention,Reduction in risk of need for BPH-related surgery
Mild to moderate pain,Pain accompanied by fever
1 capsule (0.5 mg dutasteride/0.4 mg tamsulosin) orally once daily, 30 minutes after the same meal each day.
One or two tablets (acetaminophen 300 mg/codeine 30 mg per tablet) orally every 4-6 hours as needed for pain; maximum 12 tablets daily.
Dutasteride: 5 weeks (t½ ∼3-5 weeks) due to high tissue binding and slow elimination; Tamsulosin: 9-13 hours (t½ ∼9-13 h) in healthy subjects, prolonged in elderly (∼14-15 h).
Acetaminophen: 2–3 hours (prolonged in hepatic impairment). Codeine: 2.5–3.5 hours; metabolites: morphine 1.5–2.5 hours, codeine-6-glucuronide 3–4 hours. Clinical context: dosing interval every 4–6 hours.
Dutasteride is extensively metabolized by CYP3A4 and CYP3A5. Tamsulosin is extensively metabolized by CYP3A4 and CYP2D6.
Acetaminophen: primarily glucuronidation and sulfation in liver; minor CYP450 (CYP2E1) to toxic NAPQI. Codeine: CYP2D6 to morphine; CYP3A4 to norcodeine; glucuronidation.
Dutasteride: 40% renal, 60% fecal as metabolites; Tamsulosin: 76% renal (9% unchanged), 24% fecal as metabolites.
Acetaminophen: renal elimination of conjugated metabolites (glucuronide 60%, sulfate 30%, cysteine/mercapturate <5%), less than 5% unchanged. Codeine: renal elimination of codeine (5–15%), morphine (5–10%), norcodeine (10–20%), and conjugates; 90% excreted in urine within 24 hours.
Dutasteride: 99.0-99.5% bound to albumin and alpha-1-acid glycoprotein; Tamsulosin: 94-99% bound to alpha-1-acid glycoprotein.
Acetaminophen: 10–25% (albumin). Codeine: 7–25% (primarily albumin).
Dutasteride: 300-500 L (∼3-4 L/kg); Tamsulosin: 16 L (∼0.2 L/kg). Dutasteride’s large Vd indicates extensive tissue distribution.
Acetaminophen: 0.9 L/kg. Codeine: 3–6 L/kg (extensive tissue distribution).
Oral: Dutasteride ∼60% (capsule); Tamsulosin ∼90% (capsule, under fed conditions slightly reduced).
Oral: acetaminophen 88% (variable first-pass); codeine 50–60% (first-pass metabolism to morphine, norcodeine, and conjugates).
No dose adjustment required for mild to moderate renal impairment (GFR ≥30 m L/min). Not recommended for severe renal impairment (GFR <30 m L/min) due to lack of data.
GFR 30-50 m L/min: administer every 6 hours; GFR 10-29 m L/min: administer every 8 hours; GFR <10 m L/min: administer every 12 hours; hemodialysis: not recommended.
Contraindicated in severe hepatic impairment (Child-Pugh class C). No dose adjustment for mild to moderate impairment (Child-Pugh A or B), but use with caution.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50% and extend interval to every 8 hours; Child-Pugh C: contraindicated.
Not indicated for use in pediatric patients. Safety and efficacy not established.
For children ≥12 years: acetaminophen 10-15 mg/kg/dose and codeine 0.5-1 mg/kg/dose orally every 4-6 hours; maximum acetaminophen 75 mg/kg/day, codeine 6 mg/kg/day. For children <12 years: not recommended due to codeine safety concerns.
No specific dose adjustment recommended based on age alone. Monitor for orthostatic hypotension, dizziness, and falls risk, especially in elderly patients. Consider underlying renal and hepatic function.
Start with lowest effective dose; acetaminophen component maximum 3 g/day; consider reduced codeine dose (e.g., 15 mg) due to increased sensitivity and risk of respiratory depression; extend dosing interval to every 6-8 hours.
None.
Risk of medication errors: confusion between milligram and milliliter doses, and between codeine and acetaminophen components. Contraindicated for postoperative pain management in children following tonsillectomy/adenoidectomy due to risk of respiratory depression and death.
Use with caution in combination with other alpha-blockers due to risk of hypotension,Postural hypotension may occur, especially at initiation of therapy,Not recommended for use in women, children, or adolescents due to teratogenic risk,Evaluate for prostate cancer before initiating therapy,Dutasteride may increase risk of high-grade prostate cancer in some studies,Hepatic impairment may alter metabolism of dutasteride
Hepatotoxicity (acetaminophen overdose); respiratory depression; drug dependence; ultra-rapid metabolizers of codeine (CYP2D6) leading to morphine toxicity; concomitant CNS depressants; use in pediatric patients; avoid alcohol.
Hypersensitivity to dutasteride, tamsulosin, or any component of the formulation,Use in women of childbearing potential,Use in pediatric patients
Hypersensitivity to acetaminophen or codeine; severe respiratory depression; acute or severe asthma; paralytic ileus; post-operative pain management in children after tonsillectomy/adenoidectomy; breastfeeding (in ultra-rapid metabolizers); concomitant MAOIs.
Avoid grapefruit juice; may increase tamsulosin exposure and adverse effects. Administer with a meal (same meal consistency daily) to reduce tamsulosin-related adverse events. No other food interactions known.
Avoid alcohol; high-fat meals may delay absorption but not clinically significant.
JALYN (dutasteride/tamsulosin) is contraindicated in pregnancy. Dutasteride is a 5-alpha-reductase inhibitor that can inhibit dihydrotestosterone formation, potentially causing abnormal development of external genitalia in male fetuses. Tamsulosin is an alpha-1 blocker with limited data but potential risks. First trimester: avoid; second and third trimesters: avoid due to theoretical risk.
Acetaminophen is considered low risk in all trimesters at therapeutic doses; chronic high doses may be associated with adverse outcomes. Codeine is associated with risk of respiratory depression and neonatal withdrawal if used near term; may cause neural tube defects and other malformations with first-trimester exposure, but data are conflicting. Use lowest effective dose for shortest duration.
JALYN is not indicated for use in women. Dutasteride and tamsulosin are excreted in rat milk but no human data. M/P ratio unknown; avoid breastfeeding due to potential adverse effects in infants.
Acetaminophen is excreted into breast milk in low amounts (M/P ratio ~0.91-1.42) and is considered compatible with breastfeeding. Codeine is also excreted in breast milk; risk of infant opioid toxicity depends on maternal CYP2D6 phenotype. Ultra-rapid metabolizers may produce higher morphine levels. Use with caution, avoid in known CYP2D6 ultra-rapid metabolizers, and monitor infant for sedation and respiratory depression.
No dose adjustments are applicable because JALYN is contraindicated in pregnancy. Pharmacokinetic changes in pregnancy are irrelevant as the drug should not be used.
No routine dose adjustment needed for acetaminophen. Codeine pharmacokinetics are altered in pregnancy: increased clearance and volume of distribution may require dose adjustment; however, due to variability in CYP2D6 metabolism, individualize dosing and monitor for efficacy and toxicity. Avoid codeine in pregnancy unless alternative analgesics are ineffective.
Jalyn is a fixed-dose combination of dutasteride (5α-reductase inhibitor) and tamsulosin (α1-adrenergic antagonist) for symptomatic benign prostatic hyperplasia (BPH). Onset of symptom relief is faster than either agent alone. Tamsulosin component may cause orthostatic hypotension, especially in elderly patients; counsel to rise slowly. Dutasteride reduces serum prostate-specific antigen (PSA) by approximately 50% after 6 months; PSA levels should be interpreted accordingly. Avoid use in women of childbearing potential; dutasteride is teratogenic and can be absorbed through skin contact with capsules.
For acute pain, limit codeine to 3 days; avoid in children under 12 due to CYP2D6 ultra-rapid metabolizer risk of fatal respiratory depression; monitor for constipation; assess liver function for acetaminophen hepatotoxicity; use with caution in renal impairment.
Take Jalyn 30 minutes after the same meal each day to maintain consistent absorption.,Do not crush, chew, or open capsules; swallow whole.,Avoid grapefruit juice, which may increase tamsulosin levels.,Rise slowly from sitting or lying to prevent dizziness from low blood pressure.,Report symptoms like fainting, severe headache, or prolonged painful erection (priapism) immediately.,Do not donate blood during therapy and for 6 months after stopping due to dutasteride transfer risk.,Use reliable contraception if partner is of childbearing potential; dutasteride can cause fetal harm.
Take exactly as prescribed; do not exceed 4000 mg acetaminophen per day.,Avoid alcohol while taking this medication.,Do not use with other acetaminophen-containing products.,May cause dizziness or drowsiness; avoid driving until you know how you react.,Common side effects include constipation, nausea, and drowsiness.,Seek emergency if signs of allergic reaction or difficulty breathing occur.
No interactions on record
"Pirenzepine, a selective M1 muscarinic antagonist, reduces gastrointestinal motility and secretions, while codeine, an opioid agonist, also decreases gastrointestinal motility via mu-opioid receptors. Concurrent use leads to additive anticholinergic and opioid effects, resulting in enhanced risk of severe constipation, paralytic ileus, and central nervous system depression. Clinically, patients may experience exacerbated sedation, respiratory depression, and urinary retention."
"Ropinirole, a non-ergoline dopamine agonist used in Parkinson's disease and restless legs syndrome, may reduce the analgesic efficacy of codeine. This is likely due to pharmacodynamic antagonism at central dopamine and opioid receptors, as well as potential pharmacokinetic interactions that decrease the conversion of codeine to its active metabolite morphine via CYP2D6 inhibition by ropinirole. The resultant blunted opioid response can lead to inadequate pain control, necessitating dose adjustment or alternative therapy."
"Vemurafenib induces CYP3A4, significantly reducing the plasma concentrations of codeine, which is metabolized via CYP3A4 to its active metabolite morphine. This may diminish codeine's analgesic efficacy, potentially leading to inadequate pain control. Additionally, reduced formation of morphine may lower the risk of opioid-related adverse effects."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about JALYN vs ACETAMINOPHEN AND CODEINE PHOSPHATE, answered by our medical review team.
JALYN is a 5-Alpha Reductase Inhibitor/Alpha-1 Blocker Combination that works by Jalyn is a combination of dutasteride, a 5α-reductase inhibitor that inhibits the conversion of testosterone to dihydrotestosterone (DHT), and tamsulosin, an α1-adrenoceptor antagonist that relaxes smooth muscle in the prostate and bladder neck.. ACETAMINOPHEN AND CODEINE PHOSPHATE is a Opioid Agonist that works by Acetaminophen: centrally acting analgesic and antipyretic, possibly via inhibition of cyclooxygenase (COX) and modulation of cannabinoid receptors. Codeine: prodrug converted to morphine; mu-opioid receptor agonist.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between JALYN and ACETAMINOPHEN AND CODEINE PHOSPHATE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of JALYN is: 1 capsule (0.5 mg dutasteride/0.4 mg tamsulosin) orally once daily, 30 minutes after the same meal each day.. The standard adult dose of ACETAMINOPHEN AND CODEINE PHOSPHATE is: One or two tablets (acetaminophen 300 mg/codeine 30 mg per tablet) orally every 4-6 hours as needed for pain; maximum 12 tablets daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between JALYN and ACETAMINOPHEN AND CODEINE PHOSPHATE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. JALYN is classified as Category C. JALYN (dutasteride/tamsulosin) is contraindicated in pregnancy. Dutasteride is a 5-alpha-reductase inhibitor that can inhibit dihydrotestosterone formation, potentially causing abn. ACETAMINOPHEN AND CODEINE PHOSPHATE is classified as Category D/X. Acetaminophen is considered low risk in all trimesters at therapeutic doses; chronic high doses may be associated with adverse outcomes. Codeine is associated with risk of respirat. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.